 AUSTIN, Texas, Nov. 17, 2020 PRNewswire -- Aeglea BioTherapeutics, Inc. NASDAQ: AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in... 